MarketWatch  Apr 25  Comment 
Eli Lilly swings to a loss on higher sales, cuts 2017 EPS view
Yahoo  Apr 25  Comment 
The Indianapolis-based drugmaker reported strong first-quarter demand for its Trulicity diabetes treatment and its psoriasis drug, Taltz, as well as its Cyramza lung cancer treatment. "Lilly's new product launches, including Trulicity and Taltz,...
Reuters  Apr 25  Comment 
Eli Lilly and Co reported a bigger-than-expected quarterly adjusted profit as sales of its newest products, including a diabetes injection, more than doubled.
MarketWatch  Apr 24  Comment 
Eli Lilly & Co. said early Monday that its combination treatment improved survival rates for patients with advanced breast cancer, which was also the primary endpoint in a late-stage clinical trial. The study tested the company's abemaciclib in...
Motley Fool  Apr 17  Comment 
Shares of Incyte and Eli Lilly are reeling following the FDA's rejection of their once-daily rheumatoid arthritis pill.
New York Times  Apr 17  Comment 
We’re following major developments in the markets throughout the day. Check below for the latest updates.
MarketWatch  Apr 17  Comment 
Eli Lilly & Co. shares dropped 5.5% and Incyte Corp. shares dropped 12.7% in premarket trade Monday after the companies said that the Food and Drug Administration failed to approve their drug for moderate-to-severe rheumatoid arthritis. Eli...
Wall Street Journal  Apr 14  Comment 
Eli Lilly and Incyte said the U.S. Food and Drug Administration didn’t approve their new drug application for a rheumatoid arthritis treatment that some analysts estimate could generate more than $2 billion in annual sales.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki